Current Diabetes Reports

, Volume 8, Issue 5, pp 368–374 | Cite as

Targeting prandial hyperglycemia: How important is it and how best to do this?



The contribution of postprandial glucose (PPG) excursions to the overall hyperglycemia of patients with type 2 diabetes depends on the degree of diabetic control. PPG is a major contributor in patients with hemoglobin A1c (HbA1c) levels below 7.3%, whereas the contribution of fasting plasma glucose (FPG) is preponderant in poorly controlled patients. In addition, the loss of postprandial glycemic control precedes stepwise degradation of fasting with worsening diabetes. As a consequence, monitoring after meals is particularly important in patients with HbA1c levels ranging from 6.5% to 8%. In such patients, targeting PPG below 140 mg/dL should be one of the main objectives to achieve HbA1c less than 6.5%. The new hypoglycemic agents, such as the glucagon-like peptide-1 analogues and the dipeptidyl peptidase-4 inhibitors which have a gluco-dependent insulinotropic effect, should normally reinforce our therapeutic armamentarium for achieving the glycemic targets that should include the three components of the glucose triad: HbA1c, FPG, and PPG.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Laakso M, Lehto S: Epidemiology of macrovascular disease in diabetes. Diabetes Rev 1997, 5:294–315.Google Scholar
  2. 2.
    Stratton IM, Adler AI, Neil HAW, et al.: Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405–412.PubMedCrossRefGoogle Scholar
  3. 3.
    Sacks DB, Bruns DE, Goldstein DE, et al.: Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2002, 25:750–786.CrossRefGoogle Scholar
  4. 4.
    Monnier L, Colette C, Boniface H: Contribution of postprandial glucose to chronic hyperglycaemia: from the “glucose triad” to the trilogy of “sevens.” Diabetes Metab 2006, 32:2S11–2S16.PubMedCrossRefGoogle Scholar
  5. 5.
    Monnier L, Colette C: Glycemic variability: should we and can we prevent it? Diabetes Care 2008, 31(Suppl 2):S150–S154.PubMedCrossRefGoogle Scholar
  6. 6.
    Monnier L, Lapinski H, Colette C: contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003, 26:881–885.PubMedCrossRefGoogle Scholar
  7. 7.
    Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813–820.PubMedCrossRefGoogle Scholar
  8. 8.
    Ceriello A: Postprandial hyperglycemia and diabetes complications. Is it time to treat? Diabetes 2005, 54:1–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Colette C, Monnier L: Acute glucose fluctuations and chronic sustained hyperglycemia as risk factors for cardiovascular diseases in patients with type 2 diabetes. Horm Metab Res 2007, 39:683–686.PubMedCrossRefGoogle Scholar
  10. 10.
    International Diabetes Federation: Guideline for management of postmeal glucose. Presented at the 43rd European Association for the Study of Diabetes Annual Meeting. Amsterdam, The Netherlands. September 17–21, 2007:1–27. Available at Accessed June 16, 2008.
  11. 11.
    Dinneen S, Gerich JE, Rizza R: Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med 1992, 327:707–713.PubMedGoogle Scholar
  12. 12.
    Monnier L: Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes? Eur J Clin Invest 2000, 30(Suppl 2):3–11.PubMedGoogle Scholar
  13. 13.
    Polonsky KS, Given BD, Hirsch L, et al.: Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988, 318:1231–1239.PubMedGoogle Scholar
  14. 14.
    Monnier L, Colette C, Dunseath GJ, Owens DR: The loss of postprandial glycemic control precedes stepwise degradation of fasting with worsening diabetes. Diabetes Care 2007, 30:263–269.PubMedCrossRefGoogle Scholar
  15. 15.
    DeFronzo RA: Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988, 37:667–687.PubMedGoogle Scholar
  16. 16.
    DeFronzo RA: Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 1997, 5:177–269.Google Scholar
  17. 17.
    UK Prospective Diabetes Study Group 16: Overview of 6 year’s therapy for type 2 diabetes: a progressive disease [no authors listed]. 1995, 44:1249–1258.Google Scholar
  18. 18.
    Levy J, Atkinson AB, Bell PM, et al.: Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast diet study. Diabet Med 1998, 15:290–296.PubMedCrossRefGoogle Scholar
  19. 19.
    Monnier L, Colette C, Thuan J-F, Lapinski H: Insulin secretion and sensitivity as determinants of HbA1c in type 2 diabetes. Eur J Clin Invest 2006, 36:231–235.PubMedCrossRefGoogle Scholar
  20. 20.
    Yki-Järvinen H: Role of insulin resistance in the pathogenesis of NIDDM. Diabetologia 1995, 38:1378–1388.PubMedCrossRefGoogle Scholar
  21. 21.
    Boden G, Chen X, Urbain JL: Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM Caused by cyclic changes in hepatic glucose production. Diabetes 1996, 45:1044–1050.PubMedCrossRefGoogle Scholar
  22. 22.
    Bolli GB, Gerich JE: The dawn phenomenon: a common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus. N Engl J Med 1984, 310:746–750.PubMedGoogle Scholar
  23. 23.
    Bonora E, Corrao G, Bagnardi V, et al.: Prevalence and correlates of postprandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia 2006, 49:846–854.PubMedCrossRefGoogle Scholar
  24. 24.
    Rohlfing CL, Wiedmeyer HM, Little RR, et al.: Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care 2002, 25:275–278.PubMedCrossRefGoogle Scholar
  25. 25.
    Avignon A, Radaceanu A, Monnier L: Non fasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997, 20:1822–1826.PubMedCrossRefGoogle Scholar
  26. 26.
    Bonora E, Calcaterra F, Lombardi S, et al.: Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care 2001, 24:2023–2029.PubMedCrossRefGoogle Scholar
  27. 27.
    The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003, 26(Suppl 1):S5–S20.Google Scholar
  28. 28.
    Monnier L, Colette C, Rabasa-Lhoret R, et al.: Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care 2002, 25:737–741.PubMedCrossRefGoogle Scholar
  29. 29.
    Buckingham B, Block J, Wilson DM: Continuous glucose monitoring. Curr Opin Endocrinol Diabetes 2005, 12:273–279.Google Scholar
  30. 30.
    Lebovitz HE, Austin MM, Blonde L, et al.: ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract 2006, 12(Suppl 1):6–12.PubMedGoogle Scholar
  31. 31.
    The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977–986.CrossRefGoogle Scholar
  32. 32.
    Ceriello A, Hanefeld M, Leiter L, et al.: Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004, 164:2090–2095.PubMedCrossRefGoogle Scholar
  33. 33.
    Bonora E, Muggeo M: Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes, the epidemiologic evidence. Diabetologia 2001, 44:2107–2114.PubMedCrossRefGoogle Scholar
  34. 34.
    Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE Study Group [no authors listed]. Lancet 1999, 354:617–621.CrossRefGoogle Scholar
  35. 35.
    Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999, 22:233–240.PubMedCrossRefGoogle Scholar
  36. 36.
    Cavalot F, Petrelli A, Traversa M, et al.: Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006, 91:813–819.PubMedCrossRefGoogle Scholar
  37. 37.
    Lachin JM, Genuth S, Nathan DM, et al.: Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited. Diabetes 2008, 57:995–1001.PubMedCrossRefGoogle Scholar
  38. 38.
    Hanefeld M, Fisher S, Schulze J, et al.: Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Interventional Study, 11-year follow-up. Diabetologia 1996, 39:1577–1583.PubMedCrossRefGoogle Scholar
  39. 39.
    Esposito K, Giugliano D, Nappo F, Marfella R: Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004, 110:214–219.PubMedCrossRefGoogle Scholar
  40. 40.
    Chiasson JL, Josse RG, Gomis R, et al.: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003, 290:480–494.CrossRefGoogle Scholar
  41. 41.
    Hanefeld M, Chiasson JL, Koehler C, et al.: Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004, 35:1073–1078.PubMedCrossRefGoogle Scholar
  42. 42.
    Monnier L, Colette C, Lapinski H, Boniface H: Self-monitoring of blood glucose in diabetic patients: from the least common denominator to the greatest common multiple. Diabetes Metab 2004, 20:113–119.CrossRefGoogle Scholar
  43. 43.
    Wolever TM: The glycemic index. In: Aspects of Some Vitamins, Minerals and Enzymes in Health and Disease. Edited by Bourne GH. Basel, Switzerland: Karger; 1990:120–185.Google Scholar
  44. 44.
    Nathan DM: Finding new treatments for diabetes—how many, how fast…how good? N Engl J Med 2007, 356:437–440.PubMedCrossRefGoogle Scholar
  45. 45.
    Breuer HW: Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes. Int J Clin Pharmacol Ther 2003, 41:421–440.PubMedGoogle Scholar
  46. 46.
    Culy CR, Jarvis B: Repaglinide: a review of its therapeutic use in type 2 diabetes. Drugs 2001, 61:1625–1660.PubMedCrossRefGoogle Scholar
  47. 47.
    Sinclair EM, Drucker DJ: Glucagon-like peptide 1 agonists and dipeptidyl peptidase IV inhibitors: new therapeutic agents for the treatment of type 2 diabetes. Curr Opin Endocrinol Diabetes 2005, 12:146–151.CrossRefGoogle Scholar
  48. 48.
    Hirsch IB: Insulin analogs. N Engl J Med 2005, 352:174–183.PubMedCrossRefGoogle Scholar
  49. 49.
    Monnier L, Colette C, Owens DR: Type 2 diabetes: a well characterized but suboptimally controlled disease. Can we bridge the divide? Diabetes Metab 2008, 34:207–216.PubMedCrossRefGoogle Scholar
  50. 50.
    Nathan DM, Buse JB, Davidson MB, et al.: Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care 2006, 29:1963–1972.PubMedCrossRefGoogle Scholar
  51. 51.
    Lebovitz HE: Insulin secretagogues: old and new. Diabetes Rev 1999, 7:139–153.Google Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Laboratory of Human NutritionUniversity Institute of Clinical ResearchMontpellier Cedex 5France

Personalised recommendations